Immuneering (IMRX) Equity Ratio (2020 - 2024)
Historic Equity Ratio for Immuneering (IMRX) over the last 5 years, with Q3 2024 value amounting to 0.84.
- Immuneering's Equity Ratio fell 782.27% to 0.84 in Q3 2024 from the same period last year, while for Sep 2024 it was 0.84, marking a year-over-year decrease of 782.27%. This contributed to the annual value of 0.88 for FY2023, which is 164.5% down from last year.
- Latest data reveals that Immuneering reported Equity Ratio of 0.84 as of Q3 2024, which was down 782.27% from 0.86 recorded in Q2 2024.
- Over the past 5 years, Immuneering's Equity Ratio peaked at 0.96 during Q3 2021, and registered a low of 0.66 during Q2 2021.
- In the last 5 years, Immuneering's Equity Ratio had a median value of 0.91 in 2023 and averaged 0.7.
- As far as peak fluctuations go, Immuneering's Equity Ratio surged by 25991.46% in 2021, and later tumbled by 782.27% in 2024.
- Over the past 5 years, Immuneering's Equity Ratio (Quarter) stood at 0.59 in 2020, then skyrocketed by 259.91% to 0.94 in 2021, then dropped by 4.06% to 0.9 in 2022, then dropped by 1.65% to 0.88 in 2023, then fell by 4.64% to 0.84 in 2024.
- Its Equity Ratio stands at 0.84 for Q3 2024, versus 0.86 for Q2 2024 and 0.89 for Q1 2024.